Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

other comprehensive income related to the recovery of fair value for four of the securities.

The net decrease in cash and short-term investments of $2.7 million was principally due to cash spent for operations and cash paid for principal and interest totaling $12.1 million related to the retirement of $17.0 million of convertible debt, which were partially offset by net proceeds from the sale of common stock to Cadila of $10.7 million and proceeds from the sale of stock under the ATM program of $14.0 million. Novavax believes that based on the balance of cash and short-term investments at June 30, 2009, along with the proceeds from its transaction with ROVI of $3.0 million and the proceeds of $8.0 million received from additional sales of stock under the ATM program in July 2009, it has sufficient funds to execute its current business plan for at least the next twelve months. Novavax may pursue additional funding through the potential sale of equity securities, other non-dilutive financing, or additional partnering agreements, as opportunities arise.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Conference Call

Novavax's management will host its quarterly conference call at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) today. The live conference call will be accessible via Novavax's website at www.novavax.com under Investor/Events or by tele
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 ... ) has announced the addition of the  ... And Other 2-D Nanomaterials "  report to ... , ,CNTs and graphene are the strongest, ... man, with a performance-per-weight greater than any ...
(Date:10/22/2014)... and BOSTON , Oct. 22, 2014 ... leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical ... exclusive option to acquire Rhythm,s wholly owned subsidiary, Rhythm ... ghrelin agonist, for the treatment of diabetic gastroparesis and ... completed a successful Phase 2 trial of relamorelin for ...
(Date:10/22/2014)... October 21, 2014 Shimadzu Scientific Instruments ... data tool for the pain management and clinical markets. ... processing and review by allowing users to highlight and ... , QuantAnalytics allows analysts to filter results by ... data processing by eliminating the need to sift through ...
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
Breaking Biology Technology:The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... Shareholders Re-elect Directors and Ratify Auditor at Annual Meeting, ... Directors,of Baxter International Inc. (NYSE: BAX ) today ... Annual Meeting of Shareholders,held earlier today., Baxter,s Board ... of Baxter common stock. This payment represents a continuation ...
... 6 There are a lot of steps,between a ... force must be involved with many of those steps ... re-launch effort,according to a study by benchmarking leader Best ... force? Half of the companies that,participated in the research ...
... - Dalton Pharma Services, a privately ... Fisher Scientific,have entered into an agreement ... proprietary,Thermo Fisher manufacturing process to produce ... enzyme-based technology developed at Thermo Fisher,Scientific,s ...
Cached Biology Technology:Invigorated Sales Force Key to a Successful Re-Launch 2Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development 2Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development 3
(Date:10/16/2014)... severe respiratory tract infections and worldwide claims the ... VIB and Ghent University have succeeded in developing ... virus infection. , Xavier Saelens (VIB/UGent): "We ... way for the development of a novel approach ... suffering in numerous small children and elderly people." ...
(Date:10/15/2014)... N.Y. , Oct. 15, 2014 ... solutions for home and community-based care, today announced ... of implementing Sandata,s Santrax® Electronic Visit Verification™ Solution ... Services is a home health company founded in ... Texas . The study ...
(Date:10/15/2014)... Johannes Gutenberg University Mainz (JGU) as a full ... to maintain a significant nationwide standing in the ... of Johannes Gutenberg University Mainz as a full ... the national and international competition for the best ... can be proud that Mainz University has been ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... stiff after middle age, a new study has revealed., In ... for the effects of obesity. But after middle age, this ... fat rises potentially increasing the risk of dying from ... body fat may be related to the total number of ...
... 14, 2013 /PRNewswire-iReach/ -- With specialized home health care, ... dementia -- can remain in their homes instead of ... is often preferable for the patients themselves and their ... visiting caregivers, is now providing specialized dementia and Alzheimer,s ...
... -- Recent studies that examine links between sodium consumption and ... very high levels some Americans consume now, but evidence from ... below 2,300 mg per day, says a new report from ... past several decades to reduce dietary intake of sodium, a ...
Cached Biology News:Body fat hardens arteries after middle age 2AegisCare Offers Specialized Home Health Care for Dementia and Alzheimer's Patients 2Studies support population-based efforts to lower excessive dietary sodium intakes 2Studies support population-based efforts to lower excessive dietary sodium intakes 3
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... Sensitive Bio (for heat-labile and very volatile ... to specific applications of molecular biology and ... heat-labile samples. The RC systems can be ... and a wide selection of rotors (eliminating ...
Biology Products: